Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer-Reference-Cited by-同舟云学术

Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer

Published:2008-04 Issue:4 Volume:19 Page:729-733
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Park S.H.,Nam E.,Park J.,Cho E.K.,Shin D.B.,Lee J.H.,Lee W.K.,Chung M.,Lee S.I.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/4/729/579012/mdm502.pdf

Reference21 articles.

1. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer;Pyrhonen;Br J Cancer,1995

2. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer;Glimelius;Ann Oncol,1997

3. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer;Webb;J Clin Oncol,1997

4. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group;Van Cutsem;J Clin Oncol,2006

5. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial;Kohne;Br J Cancer,2003

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leitlinienreport zur S3-Leitlinie Magenkarzinom – „Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs“;Zeitschrift für Gastroenterologie;2019-12

2. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis;BMC Cancer;2019-11-20

3. Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis;JNCI: Journal of the National Cancer Institute;2019-06-28

4. TOXview: a novel graphical presentation of cancer treatment toxicity profiles;Acta Oncologica;2019-04-24

5. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma;Investigational New Drugs;2018-05-04